Caribou Biosciences (CRBU) Cash & Equivalents (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Cash & Equivalents data on file, last reported at $12.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $12.1 million, down 59.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (down 59.01% YoY), and the FY2025 annual result was $12.4 million, down 24.14% from the prior year.
• Cash & Equivalents declined to $12.1 million in Q1 2026 per CRBU's latest filing, from $12.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $147.6 million in Q1 2022 and troughed at $11.1 million in Q3 2025.
• A 5-year average of $52.9 million and a median of $49.4 million in 2024 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 243695.65% in 2022 and fell as far as 81.14% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $58.3 million in 2022, then dropped by 12.3% to $51.2 million in 2023, then tumbled by 68.15% to $16.3 million in 2024, then declined by 24.14% to $12.4 million in 2025, then retreated by 2.45% to $12.1 million in 2026.
• Business Quant data shows CRBU's Cash & Equivalents at $12.1 million in Q1 2026, $12.4 million in Q4 2025, and $11.1 million in Q3 2025.